BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22736234)

  • 1. Molecular characteristics of glioblastoma with 1p/19q co-deletion.
    Mizoguchi M; Yoshimoto K; Ma X; Guan Y; Hata N; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
    Brain Tumor Pathol; 2012 Jul; 29(3):148-53. PubMed ID: 22736234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
    Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
    Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.
    Jesionek-Kupnicka D; Szybka M; Potemski P; Kulczycka-Wojdala D; Jaskólski D; Bieńkowski M; Skowroński W; Papierz W; Kordek R; Zawlik I
    Pol J Pathol; 2013 Dec; 64(4):268-75. PubMed ID: 24375041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis.
    Durand KS; Guillaudeau A; Weinbreck N; DeArmas R; Robert S; Chaunavel A; Pommepuy I; Bourthoumieu S; Caire F; Sturtz FG; Labrousse FJ
    Mod Pathol; 2010 Apr; 23(4):619-28. PubMed ID: 20081802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastomas with an oligodendroglial component: a pathological and molecular study.
    He J; Mokhtari K; Sanson M; Marie Y; Kujas M; Huguet S; Leuraud P; Capelle L; Delattre JY; Poirier J; Hoang-Xuan K
    J Neuropathol Exp Neurol; 2001 Sep; 60(9):863-71. PubMed ID: 11556543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
    Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.
    Jiang H; Ren X; Wang J; Zhang Z; Jia W; Lin S
    J Neurooncol; 2014 Jan; 116(2):395-404. PubMed ID: 24264532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.
    Sathornsumetee S; Cheunsuchon P; Sangruchi T
    World Neurosurg; 2016 Jul; 91():518-523.e1. PubMed ID: 26960282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
    Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
    Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
    Ha SY; Kang SY; Do IG; Suh YL
    J Neurooncol; 2013 May; 112(3):439-48. PubMed ID: 23412777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.